RBD-7022

主要研究目的：评价不同剂量QLC7401在接受优化降脂治疗控制不佳的LDL-C升高的原发性高胆固醇血症或混合型高脂血症受试者中的安全性、耐受性和有效性。 次要研究目的：评估QLC7401的药效动力学（PD）特征；评估QLC7401的免疫原性。

This is a randomized, single blind, placebo controlled, single center phase I study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of subcutaneously administered RBD7022 in participants with normal or elevated LDL-c cholesterol. The study will be performed in 2 phases: single ascending dose (SAD) phase and multiple ascending doses (MAD) phase in participants. The decision to escalate to subsequent dose levels will be made by the SRC based on the review of all available safety information in each cohort.